Fermentation captures 84% of Europe’s alternative protein investment as funding rebounds
Europe’s alternative protein companies raised €236 million (US$274 million) in private investment during the first half of 2026, up 56% year on year, as fermentation companies attracted the overwhelming majority of capital flowing into the sector.
• European alternative protein companies raised €236 million in private investment during H1 2026, representing a 56% increase compared with the same period in 2025.
• Precision and biomass fermentation companies raised a combined €199 million, accounting for roughly 84% of all private investment secured by European alternative protein companies.
• Plant-based and cultivated meat companies each raised €18 million, while fermentation companies also secured €67 million in grants alongside growing use of blended financing.
The figures, based on GFI Europe’s analysis of Net Zero Insights data, revealed a European market increasingly dominated by fermentation and characterized by fewer but larger funding rounds.
Precision fermentation companies raised €100 million (US$117 million) during the first six months of the year, already exceeding the €97 million raised across the whole of 2025.
Biomass fermentation companies attracted a further €99 million (US$115 million), compared with €61 million throughout 2025.
Together, the two fermentation categories therefore accounted for approximately 84% of the €236 million invested privately in European alternative protein companies during the period.
Among the larger transactions were a €25 million round for French precision fermentation company Verley and €18 million for Dutch biomass fermentation specialist The Protein Brewery.
The private investment was accompanied by substantial public funding. Fermentation startups secured €67 million in grants during H1 2026, compared with €45 million in grant funding received by alternative protein companies across all categories during the equivalent period last year.
Several companies have combined public and private capital or government-backed lending as they move toward larger-scale production.
Dutch precision fermentation company Vivici received €12.5 million through the European Innovation Council Accelerator Programme, combining a €2.5 million grant with €10 million in equity.
Meanwhile, a European consortium led by UK-based Adamo Foods received a €10 million grant through the EU-funded Circular Bio-Based Europe Joint Undertaking to support scale-up of its fermentation-derived steak technology.
The picture was markedly different elsewhere in the alternative protein sector.
European cultivated meat companies raised €18 million during H1 2026, approaching the €20 million secured throughout 2025 but remaining below previous investment peaks.
Germany’s Innocent Meat raised €6 million to develop automated production technology, pursue regulatory approval and begin construction of a demonstration facility, while cultivated pet food company Meatly secured €12 million for a large-scale production facility.
Plant-based companies also raised €18 million, representing a steep decline from the €61 million invested during H1 2025.
GFI Europe said some companies were consolidating through acquisitions and mergers, while others had reached the capital-intensive stage of moving from pilot production toward industrial capacity.
The organization argued that this stage of development was poorly suited to conventional venture capital models, particularly where companies needed to finance expensive manufacturing infrastructure with longer routes to returns.
The overall European increase also contrasted with the global picture. European startups accounted for more than three-quarters of global alternative protein investment during H1 2026, according to GFI Europe, but worldwide funding declined from €341 million in H1 2025 to €306 million during the corresponding period this year.
The number of deals globally also halved, indicating that investors were concentrating capital among a smaller group of companies.
GFI Europe said the data strengthened the case for financing structures combining equity, grants, loans and other forms of public and private capital to spread the risks associated with industrial scale-up.
Fermentation appears to be the furthest advanced in demonstrating that model, with companies increasingly combining conventional investment rounds with grants and government-backed financing for demonstration and commercial facilities.
Whether similar structures can unlock capital for plant-based and cultivated meat companies could now prove critical as more European alternative protein businesses move from technology development toward commercial manufacturing.
If you liked this, check these out...
• MAASH raises €12.15 million to launch mycoprotein demonstration plant
• Millow raises €2 million as commercial mycelium protein production gets underway
• Inaara NeoFoods raises US$2.4 million seed round to scale AI-driven farm-to-formulation plant protein platform
Join Us At One Of Our Upcoming Events
If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com
